Glucagon-Like Peptide-1 Agonist Use in Adults With Congenital Heart Disease DOI

Rashmi Thapa,

Kyla Lara-Breitinger, Francisco López-Jiménez

и другие.

JACC Advances, Год журнала: 2025, Номер 4(4), С. 101674 - 101674

Опубликована: Март 25, 2025

Язык: Английский

Evolving role of double and triple therapy with GLP-1 receptor agonists in obesity and cardiovascular disease DOI
Phelopater Sedrak, Raj Verma,

Meena Verma

и другие.

Canadian Journal of Cardiology, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
Anti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance DOI

Josephine Harrington,

Stormi E. Gale, Amanda R. Vest

и другие.

Circulation Heart Failure, Год журнала: 2024, Номер 17(9)

Опубликована: Авг. 1, 2024

Obesity is a significant risk factor for heart failure (HF) development, particularly HF with preserved ejection fraction and as result, many patients also have obesity. There growing clinical interest in optimizing strategies the management of obesity across spectrums both disease severity. The emergence anti-obesity medications cardiovascular outcomes benefits, principally glucagon-like peptide-1 receptor agonists, has made it possible to study impact baseline conditions, including HF. However, trials data supporting safety efficacy treating currently limited fraction, but do confirm weight loss this patient population well improvements functional status, biomarkers inflammation stability. Here, we review current available surrounding HF, limitations evidence ongoing areas investigation, summarize next phase emerging provide practical advice multidisciplinary

Язык: Английский

Процитировано

3
Response by Kosiborod et al to Letter Regarding Article, “Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial” DOI
Mikhail Kosiborod, Mark C. Petrie, Barry A. Borlaug

и другие.

Circulation, Год журнала: 2024, Номер 150(10)

Опубликована: Сен. 3, 2024

Язык: Английский

Процитировано

3
SERCA2a dysfunction in the pathophysiology of heart failure with preserved ejection fraction: a direct role is yet to be established DOI Creative Commons

Adam Kia Shooshtarian,

Kevin O’Gallagher, Ajay M. Shah

и другие.

Heart Failure Reviews, Год журнала: 2025, Номер unknown

Опубликована: Янв. 23, 2025

Abstract With rising incidence, mortality and limited therapeutic options, heart failure with preserved ejection fraction (HFpEF) remains one of the most important topics in cardiovascular medicine today. Characterised by left ventricular diastolic dysfunction partially due to impaired Ca 2+ homeostasis, ion channel particular, SarcoEndoplasmic Reticulum -ATPase (SERCA2a), may play a significant role its pathophysiology. A better understanding complex mechanisms interplaying contribute SERCA2a will help develop treatments targeting it thus address growing clinical challenge HFpEF poses. This review examines conflicting evidence present for changes expression activity HFpEF, explores potential underlying mechanisms, finally evaluates drug gene therapy trials failure. Recent positive results from involving widely used anti-diabetic agents such as sodium-glucose co-transporter protein 2 inhibitors (SGLT2i) glucagon-like peptide-1 (GLP-1) agonists offer advancement management. The interplay between these regulation presents novel angle that could open new avenues modulating function; however, mechanistic research this emerging field is limited. Overall, direct undetermined, highlighting need well-designed pre-clinical studies robust trials.

Язык: Английский

Процитировано

0
Glucagon-Like Peptide-1 Agonist Use in Adults With Congenital Heart Disease DOI

Rashmi Thapa,

Kyla Lara-Breitinger, Francisco López-Jiménez

и другие.

JACC Advances, Год журнала: 2025, Номер 4(4), С. 101674 - 101674

Опубликована: Март 25, 2025

Язык: Английский

Процитировано

0